Stephen J Balevic1,2, Michael Cohen-Wolkowiez3,4, Amanda M Eudy3,4, Thomas P Green3,4, Laura E Schanberg3,4, Megan E B Clowse3,4. 1. From the departments of Internal Medicine and Pediatrics, Duke University, and Duke Clinical Research Institute, Durham, North Carolina; Department of Pediatrics, Children's Hospital of Chicago, Chicago, Illinois, USA. Stephen.balevic@duke.edu. 2. S.J. Balevic, MD, MHS, Assistant Professor, departments of Internal Medicine and Pediatrics, Duke University Medical Center and Duke Clinical Research Institute; M. Cohen-Wolkowiez, MD, PhD, Professor, Department of Pediatrics, Duke University Medical Center and Duke Clinical Research Institute; A.M. Eudy, PhD, Postdoctoral Fellow, Department of Internal Medicine, Duke University Medical Center; T.P. Green, MD, Professor and Chair, Department of Pediatrics, Children's Hospital of Chicago; L.E. Schanberg, MD, Professor, Department of Pediatrics, Duke University Medical Center; M.E. Clowse, MD, MPH, Associate Professor, Department of Internal Medicine, Duke University Medical Center. Stephen.balevic@duke.edu. 3. From the departments of Internal Medicine and Pediatrics, Duke University, and Duke Clinical Research Institute, Durham, North Carolina; Department of Pediatrics, Children's Hospital of Chicago, Chicago, Illinois, USA. 4. S.J. Balevic, MD, MHS, Assistant Professor, departments of Internal Medicine and Pediatrics, Duke University Medical Center and Duke Clinical Research Institute; M. Cohen-Wolkowiez, MD, PhD, Professor, Department of Pediatrics, Duke University Medical Center and Duke Clinical Research Institute; A.M. Eudy, PhD, Postdoctoral Fellow, Department of Internal Medicine, Duke University Medical Center; T.P. Green, MD, Professor and Chair, Department of Pediatrics, Children's Hospital of Chicago; L.E. Schanberg, MD, Professor, Department of Pediatrics, Duke University Medical Center; M.E. Clowse, MD, MPH, Associate Professor, Department of Internal Medicine, Duke University Medical Center.
Abstract
OBJECTIVE: Pregnancies in women with active rheumatic disease often result in poor neonatal outcomes. Hydroxychloroquine (HCQ) reduces disease activity and flares; however, pregnancy causes significant physiologic changes that may alter HCQ levels and lead to therapeutic failure. Therefore, our objective was to evaluate HCQ concentrations during pregnancy and relate levels to outcomes. METHODS: We performed an observational study of pregnant patients with rheumatic disease who were taking HCQ from a single center during 2013-2016. Serum samples were analyzed using high-performance liquid chromatography/mass spectrometry. Primary HCQ exposure was categorized as nontherapeutic (≤ 100 ng/ml) or therapeutic (> 100 ng/ml). Categorical outcomes were analyzed using Fisher's exact test and continuous outcomes using linear regression models, Wilcoxon signed-rank test, Kruskal-Wallis test, t test, and ANOVA. RESULTS: We analyzed 145 samples from 50 patients with rheumatic disease, 56% of whom had systemic lupus erythematosus (SLE). HCQ concentration varied widely among individuals at each trimester. Mean physician's global assessment scores in patients with SLE were significantly higher in those with average drug levels ≤ 100 ng/ml compared to > 100 ng/ml (0.93 vs 0.32, p = 0.01). Of patients with SLE, 83% with average drug levels ≤ 100 ng/ml delivered prematurely (n = 6), compared to only 21% with average levels > 100 ng/ml (n = 19; p = 0.01). HCQ levels were not associated with prematurity or disease activity in non-SLE patients. CONCLUSION: With both high and low HCQ levels associated with preterm birth and disease activity in SLE, further study is necessary to understand HCQ disposition throughout pregnancy and to clarify the relationship between drug levels and outcomes.
OBJECTIVE: Pregnancies in women with active rheumatic disease often result in poor neonatal outcomes. Hydroxychloroquine (HCQ) reduces disease activity and flares; however, pregnancy causes significant physiologic changes that may alter HCQ levels and lead to therapeutic failure. Therefore, our objective was to evaluate HCQ concentrations during pregnancy and relate levels to outcomes. METHODS: We performed an observational study of pregnant patients with rheumatic disease who were taking HCQ from a single center during 2013-2016. Serum samples were analyzed using high-performance liquid chromatography/mass spectrometry. Primary HCQ exposure was categorized as nontherapeutic (≤ 100 ng/ml) or therapeutic (> 100 ng/ml). Categorical outcomes were analyzed using Fisher's exact test and continuous outcomes using linear regression models, Wilcoxon signed-rank test, Kruskal-Wallis test, t test, and ANOVA. RESULTS: We analyzed 145 samples from 50 patients with rheumatic disease, 56% of whom had systemic lupus erythematosus (SLE). HCQ concentration varied widely among individuals at each trimester. Mean physician's global assessment scores in patients with SLE were significantly higher in those with average drug levels ≤ 100 ng/ml compared to > 100 ng/ml (0.93 vs 0.32, p = 0.01). Of patients with SLE, 83% with average drug levels ≤ 100 ng/ml delivered prematurely (n = 6), compared to only 21% with average levels > 100 ng/ml (n = 19; p = 0.01). HCQ levels were not associated with prematurity or disease activity in non-SLEpatients. CONCLUSION: With both high and low HCQ levels associated with preterm birth and disease activity in SLE, further study is necessary to understand HCQ disposition throughout pregnancy and to clarify the relationship between drug levels and outcomes.
Authors: Pavandeep Mehat; Mohammad Atiquzzaman; John M Esdaile; Antonio AviÑa-Zubieta; Mary A De Vera Journal: Arthritis Care Res (Hoboken) Date: 2017-09-21 Impact factor: 4.794
Authors: Monika Østensen; Laura Andreoli; Antonio Brucato; Irene Cetin; Christina Chambers; Megan E B Clowse; Nathalie Costedoat-Chalumeau; Maurizio Cutolo; Radboud Dolhain; M H Fenstad; Frauke Förger; Marie Wahren-Herlenius; Guillermo Ruiz-Irastorza; Hege Koksvik; Catherine Nelson-Piercy; Yehuda Shoenfeld; Angela Tincani; Peter M Villiger; Marianne Wallenius; Michael von Wolff Journal: Autoimmun Rev Date: 2014-12-30 Impact factor: 9.754
Authors: Chi Chiu Mok; Hannah J Penn; Kar Li Chan; Sau Mei Tse; Loralie J Langman; Paul J Jannetto Journal: Arthritis Care Res (Hoboken) Date: 2016-07-27 Impact factor: 4.794
Authors: Yaël A de Man; Johanna M W Hazes; Hugo van der Heide; Sten P Willemsen; Christianne J M de Groot; Eric A P Steegers; Radboud J E M Dolhain Journal: Arthritis Rheum Date: 2009-11
Authors: Mehret Birru Talabi; Megan E B Clowse; Susan J Blalock; Megan Hamm; Sonya Borrero Journal: Arthritis Care Res (Hoboken) Date: 2020-03 Impact factor: 4.794
Authors: Kristin Palmsten; Gretchen Bandoli; Gabriela Vazquez-Benitez; Christina D Chambers Journal: Arthritis Care Res (Hoboken) Date: 2022-05-20 Impact factor: 5.178
Authors: Henrik Carlsson; Karin Hjorton; Sandy Abujrais; Lars Rönnblom; Torbjörn Åkerfeldt; Kim Kultima Journal: Arthritis Res Ther Date: 2020-06-01 Impact factor: 5.156
Authors: Stephen J Balevic; Daniel Weiner; Megan E B Clowse; Amanda M Eudy; Anil R Maharaj; Christoph P Hornik; Michael Cohen-Wolkowiez; Daniel Gonzalez Journal: Lupus Sci Med Date: 2022-01
Authors: Megan E B Clowse; Amanda M Eudy; Stephen Balevic; Gillian Sanders-Schmidler; Andrzej Kosinski; Rebecca Fischer-Betz; Dafna D Gladman; Yair Molad; Cecilia Nalli; Abir Mokbel; Angela Tincani; Murray Urowitz; Caroline Bay; Megan van Noord; Michelle Petri Journal: Lupus Sci Med Date: 2022-03
Authors: Tierney Wolgemuth; Olivia M Stransky; Alaina Chodoff; Traci M Kazmerski; Megan E B Clowse; Mehret Birru Talabi Journal: Arthritis Care Res (Hoboken) Date: 2021-07-14 Impact factor: 5.178
Authors: Stephen J Balevic; Christoph P Hornik; Thomas P Green; Megan E B Clowse; Daniel Gonzalez; Anil R Maharaj; Laura E Schanberg; Amanda M Eudy; Geeta K Swamy; Brenna L Hughes; Michael Cohen-Wolkowiez Journal: J Rheumatol Date: 2020-05-11 Impact factor: 5.346
Authors: Meredith M Howley; Martha M Werler; Sarah C Fisher; Alissa R Van Zutphen; Suzan L Carmichael; Cheryl S Broussard; Dominique Heinke; Elizabeth C Ailes; Shannon M Pruitt; Jennita Reefhuis; Allen A Mitchell; Marilyn L Browne Journal: Birth Defects Res Date: 2021-07-23 Impact factor: 2.661